Fresenius acquired stakes in a portfolio of Chinese hospital operators.

Fresenius Medical Care, the world’s largest provider of dialysis products and services, acquired a 70% share of Guangzhou KangNiDaiSi Medical Investment Co., Ltd, which focuses on dialysis and related chronic disease services, 55% stakes in Henan Aishen Hospital Management Co. Ltd and Aishen Beijing Hospital Management Co., Ltd, two dialysis centre operators and a 60% share of Daqing Kangda Dialysis Center. Financial terms of the acquisitions were not disclosed. Rice Powell, CEO of Fresenius Medical Care, said: “Fresenius Medical Care is committed to improving access to world-leading dialysis technology and chronic disease management services for the more than 120 million people in China who are living with chronic kidney disease. These acquisitions mark an important strategic step in our business development in China. As the second largest product market, China is already today an important business growth driver for Fresenius Medical Care. We have been continuously investing in enhancing our product range within the local market. We have also started to enter the provider business to introduce advanced dialysis services and operations management in China.”